Outbound Deals
Chinese biopharmas may reach ~$60B in outbound deals by end-2025, led by Hengrui–GSK, 3SBio–Pfizer, XtalPi–DoveTree, and Hansoh–Regeneron. Oncology, obesity, and AI fuel China’s rise as a global licensing powerhouse, with top deals and trends highlighted.
Bispecific Antibodies
With blockbuster deals by 3SBio, BioNTech, and Akeso, emerging Chinese PD-1/VEGF bispecifics like RC148, HB0025, JS207, and CS2009 are primed for billion-dollar licensing opportunities.
Ivonescimab
Akeso’s Ivonescimab achieves pivotal OS milestone in EGFR-mutant NSCLC, outperforming Keytruda and cementing its role in the PD-1/VEGF bispecific market.
China biopharma
A decade of transformation in China’s biopharma industry: first-in-class drugs, expanded clinical pipelines, R&D talent, and billion-dollar global partnerships reshaping pharma leadership.
Outbound Deals
Witness the new era of global biotech collaboration as China's top outbound deals inject billions into innovation. From 3SBio's $1.25B Pfizer licensing to BioNTech's acquisition of Biotheus, explore key themes in bispecifics, ADCs, and strategic partnerships.
Bispecific Antibodies
Bispecific antibodies are reshaping oncology and beyond. By 2025, 20 products are approved, with 2024 sales topping $126.5B led by Hemlibra and Vabysmo. China leads the pipeline with 35+ trials, two domestic approvals, and global partnerships.
Bispecific Antibodies
China’s BsAb deals hit $9.26B in H1 2025. Innovent, Hengrui, and SystImmune shift beyond PD-(L)1/VEGF to Ang2/VEGF, T-cell engagers, and novel dual-pathway drugs.